The recent development of mutation-specific KRAS G12C inhibitors highlighted the heterogeneous structural and functional consequences of specific NRAS and KRAS mutations [5, 68] and we may hypothesize that these different mutations may confer specific metabolic vulnerabilities to AML cells accounting for their sensitivity to trametinib or pyrvinium. This evidence concerns the gene NRAS and acute myeloid leukemia.